Coya Therapeutics, Inc. (COYA) Financials
Annual revenue, profitability and per-share results for Coya Therapeutics, Inc., as reported in SEC filings.
Revenue • FY2025
$7.95M
▲ 123.6%YoY
Net income • FY2025
-$21.23M
▼ 42.6%YoY
Diluted EPS • FY2025
$-1.27
▼ 29.6%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $7.95M | -$21.23M | — | $-1.27 | — | -283.9% | +123.6% |
| FY2024 | $3.55M | -$14.88M | — | $-0.98 | — | -485.4% | -40.8% |
| FY2023 | $6M | -$7.99M | — | $-0.79 | — | -131.7% | — |
| FY2022 | $0 | -$12.24M | — | $-4.73 | — | — | — |
Figures as reported in Coya Therapeutics, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a COYA filing.
Get an email when COYA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.